Cite
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
MLA
Pandha, Hardev S., et al. “Dendritic Cell Immunotherapy for Urological Cancers Using Cryopreserved Allogeneic Tumour Lysate-Pulsed Cells: A Phase I/II Study.” BJU International, vol. 94, no. 3, Aug. 2004, pp. 412–18. EBSCOhost, https://doi.org/10.1111/j.1464-410X.2004.04922.x.
APA
Pandha, H. S., John, R. J., Hutchinson, J., James, N., Whelan, M., Corbishley, C., & Dalgleish, A. G. (2004). Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU International, 94(3), 412–418. https://doi.org/10.1111/j.1464-410X.2004.04922.x
Chicago
Pandha, Hardev S., Robert J. John, James Hutchinson, Nick James, Mike Whelan, Catherine Corbishley, and Angus G. Dalgleish. 2004. “Dendritic Cell Immunotherapy for Urological Cancers Using Cryopreserved Allogeneic Tumour Lysate-Pulsed Cells: A Phase I/II Study.” BJU International 94 (3): 412–18. doi:10.1111/j.1464-410X.2004.04922.x.